Home / Available CME / 17th CROI CME Newsletter

17th CROI CME Newsletter

CROI_CME_Newsletter_Static_Banner

About the Program

Program Overview
Target Audience
Learning Objectives
Course Director
Faculty
Accreditation Statement
Credit Designation
Disclosure of Conflicts of Interest
Disclosure of Unlabeled Use
Instructions for Participation and Credit
Disclaimer

Program Overview

This CME Newsletter will review and discuss the key studies on antiretroviral therapy presented at the 17th Conference on Retroviruses and Opportunistic Infections.* Contributors to this newsletter are from a distinguished faculty panel in the field of HIV, including the course director Calvin Cohen, MD, from Harvard Medical School.

This CME Newsletter is certified for CME credit for US physicians by the Postgraduate Institute for Medicine. This program is for health care providers who treat HIV-positive patients, there are no prerequisites.

Target Audience

This activity has been designed to meet the educational need of physicians involved in the care of patients with HIV infection.

Learning Objectives

Following this program, participants will be able to:

Explain the key new studies on ARV therapy presented at the 17th CROI;
Outline how to use the advances in clinical management of HIV-positive patients presented and discussed at the 17th CROI to improve patient care ;
Describe how to apply data presented and discussed at the 17th CROI regarding the treatment of ARV-naïve and experienced patients;
Analyze treatment options and construct appropriate ARV regimens.

Release Date: March 2, 2010
Expiration Date: March 1, 2011

Estimated time to complete the 17th CROI Newsletter: 1 Hour

Media: Internet

Course Director

Calvin J. Cohen, MD, MS
Research Director,
CRI New England
Clinical Instructor,
Harvard Medical School
Boston, Massachusetts

Faculty

Joseph Eron, MD,
Professor, University of North Carolina
School of Medicine
Chapel Hill, North Carolina

Jurgen Rockstroh, MD
Professor, University of Bonn
Bonn, Germany

Paul Sax, MD
Clinical Director,
Brigham and Women's Division of
Infectious Diseases and HIV Program
Associate Professor of Medicine,
Harvard Medical School
Boston, Massachusetts

Ian Frank, MD
Professor of Medicine,
Director, Antiretroviral Clinical Research
University of Pennsylvania
Philadelphia, Pennsylvania

Andrew Zolopa, MD
Associate Professor of Medicine,
Division of Infectious Diseases,
Stanford University School of Medicine
Palo Alto, California

Richard A. Elion , MD
Associate Professor of Clinical Medicine,
George Washington University Medical Center
Washington, DC

Edwin DeJesus, MD
Medical Director,
Orlando Immunology Center
Orlando, Florida

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and ViralEd, LLC. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1 Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The facultyreported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Dr. Calvin Cohen:

Sources of Funding for Research: Bristol-Myers Squibb; Gilead Sciences; Merck & Co.; Pfizer; Tibotec
Consulting Agreements: Bristol-Myers Squibb; Gilead Sciences; Merck & Co.; Pfizer; Tibotec
Speakers' Bureau: Bristol-Myers Squibb; Gilead Sciences; Merck & Co.; Tibotec

Dr. Joseph Eron:

Sources of Funding for Research: GlaxoSmithKline; Merck & Co.; Panacos; Taimed
Consulting Agreements: Bristol-Myers Squibb; Avexa; Merck & Co.; GlaxoSmithKline; Tibotec; Virco Laboratories; Pfizer; Tobira; Chimirex; Myriad
Speakers' Bureau/Honorarium Agreements: Roche; Bristol-Myers Squibb; Gilead; Merck & Co.; Tibotec (Not Active Since 1/1/09; Virco Laboratories; Gilead (Not Active)

Dr. Paul Sax:

Sources of Funding for Research: Merck & Co.; Tibotec; GlazoSmithKline
Consulting Agreements: GlaxoSmithKline; Gilead; Abbott; Bristol-Myers Squibb; Tibotec; Pfizer
Speakers' Bureau: Bristol-Myers Squibb

Dr. Ian Frank:

Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Pfizer
Speakers' Bureau: Bristol-Myers Squibb; Gilead Sciences; Tibotec

Dr. Andrew Zolopa:

Sources of Funding for Research: Gilead; Merck & Co.; Pfizer; Schering-Plough; VIRxSYS
Consulting Agreements/Advisory Boards: Bristol-Myers Squibb; Gilead; Tibotec

Dr. Richard Elion:

Sources of Funding for Research: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck & Co.; Rapid; Tibotec
Consulting Agreements: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Tibotec
Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Tibotec

Dr. Edwin DeJesus:

Sources of Funding for Research: Boehringer Ingelheim; Abbott; Achillion; Avexa; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Hoffman LaRoche; Pfizer; Merck & Co.; Schering-Plough; Taimed; Tobira; Tibotec; Vertex
Consulting Agreements: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck & Co.; Tibotec; Vertex Pharmaceuticals
Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck & Co.; Tibotec; Vertex Pharmaceuticals; Virco

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The following PIM planners and managers: Jan Hixon, RN, BSN, MS, Trace Hutchison, PharmD, Julia Kirkwood, RN, BSN, Samantha Mattiucci, PharmD and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of these activities of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), ViralEd, LLC, and Merck & Co., Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ViralEd, LLC, and Merck & Co., Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions for Participation and Credit

There are no fees for participating and receiving credit for this activity. During the period, March 2, 2010 through March 1, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form.

To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on the Submit Post-test at the bottom of the page. Your post-test will automatically be graded.

If you successfully complete the post-test (score of 70% or higher). your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you received a score of 69% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.

You may complete the Post-test on-line at www.cmeuniversity.com.

Click on "Find Post-Test/Evaluation by Course" on the navigation menu
Search by project ID 7167
Upon successfully completing the Post-test and Evaluation form, your certificate will be made available immediately.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

PIM-4C-logo_sml